Industry

Company has received Safe to Proceed letters from FDA for two clinical trials in life-threatening brain tumors, DIPG trial is open and actively recruiting, it has expanded its executive leadership team and scientific advisory board and completed a Series B funding round. OAKLAND, Calif.–(BUSINESS WIRE)–#DIPG—SonALAsense, a pioneer in the development of SONALA-001 and sonodynamic therapy … [Read more…]

– Ohio State Wexner Medical Center and Siemens Healthineers have committed to a new strategic relationship to bring the most advanced imaging and treatment technologies from Siemens Healthineers to Ohio State patient care and research centers and the surrounding communities. – The partnership: Provides advanced imaging and cutting-edge radiation oncology modalities at Outpatient Care West … [Read more…]

ANN ARBOR, Mich.–(BUSINESS WIRE)–$NDRA #NAFLD—ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the United States Patent and Trademark Office has issued a new ENDRA patent, U.S. Patent No. 11369272 (the ‘272 patent) titled “Broadband Applicator for Thermoacoustic Signal Generation.” The ‘272 patent protects TAEUS’ radiofrequency (RF) applicator … [Read more…]

— Combines NewAmsterdam’s lead clinical program obicetrapib with Menarini’s deep cardiovascular disease and regional expertise — — Total deal value of over €1 billion; including €142.5 million upfront payment and committed R&D funding plus potential milestones and double-digit royalties on net product sales in Europe — — Obicetrapib is a next-generation oral, low-dose and once-daily … [Read more…]

— Additional Phase 2b data evaluating AD109 as potential treatment for OSA anticipated in Q3 2022 — AD109 Phase 3 development program expected to be initiated in late 2022 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea (OSA) and related disorders, announced today that the … [Read more…]

GYANT’s AI-powered virtual assistant will be used to automate patient intake for more efficient engagements between providers and patients SAN FRANCISCO–(BUSINESS WIRE)–GYANT, the patient journey automation company, today announced that its automated patient intake and charting tool, Intake, will be launched with Walmart Health Virtual Care, formerly known as MeMD. GYANT’s web-enabled clinical assessment solution … [Read more…]

Cheshire-based site to bolster plasmid DNA manufacturing, supporting cell and gene therapy development WILMINGTON, Mass. & MACCLESFIELD, England–(BUSINESS WIRE)–$CRL #LIFEatCRL–Charles River Laboratories International, Inc. (NYSE: CRL) announced today the opening of its High Quality (HQ) Plasmid DNA Centre of Excellence at Bruntwood SciTech’s Alderley Park in Cheshire, United Kingdom. The expansion follows Charles River’s acquisition … [Read more…]

– Palleon and Henlius to co-develop Bifunctional HER2-Sialidase and a second bifunctional sialidase to be jointly designed – – Henlius received exclusive license for two products in China (including Hong Kong, Macau, and Taiwan); Palleon retains all other global rights – – Palleon receives upfront payment and is eligible for up to $196.5 million in … [Read more…]

Phase 1 Clinical Trial in Patients with Advanced B-Cell Malignancies Expected to Begin in the Second Half of 2022 NEW YORK–(BUSINESS WIRE)–Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that the U.S. Food and Drug Administration (FDA) cleared its investigational new drug (IND) application … [Read more…]

Positive Phase 1 results reported at the American Association for Thoracic Surgery (AATS) and the American Society of Gene and Cell Therapy (ASGCT) revealed XC001 is well tolerated at all dose levels Phase I data support XC001 therapeutic effect and potential dose response Topline Phase 2 data readout expected in February 2023 with interim results … [Read more…]